Vanguard Group’s Theravance Biopharma TBPH Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Shares
Change %
Capital Flow Portfolio Weight Portfolio Position
2025
Q2
$23.8M Buy
2,157,430
+76,967
+4% +$849K ﹤0.01% 2479
2025
Q1
$18.6M Buy
2,080,463
+69,919
+3% +$624K ﹤0.01% 2536
2024
Q4
$18.9M Sell
2,010,544
-41,145
-2% -$387K ﹤0.01% 2616
2024
Q3
$16.5M Buy
2,051,689
+49,510
+2% +$399K ﹤0.01% 2688
2024
Q2
$17M Sell
2,002,179
-683,674
-25% -$5.8M ﹤0.01% 2651
2024
Q1
$24.1M Sell
2,685,853
-803,409
-23% -$7.21M ﹤0.01% 2507
2023
Q4
$39.2M Sell
3,489,262
-350,067
-9% -$3.93M ﹤0.01% 2287
2023
Q3
$33.1M Sell
3,839,329
-379,627
-9% -$3.28M ﹤0.01% 2329
2023
Q2
$43.7M Sell
4,218,956
-1,407,770
-25% -$14.6M ﹤0.01% 2244
2023
Q1
$61M Buy
5,626,726
+67,887
+1% +$737K ﹤0.01% 2081
2022
Q4
$62.4M Sell
5,558,839
-447,294
-7% -$5.02M ﹤0.01% 2061
2022
Q3
$60.9M Sell
6,006,133
-538,673
-8% -$5.46M ﹤0.01% 2086
2022
Q2
$59.3M Sell
6,544,806
-403,141
-6% -$3.65M ﹤0.01% 2110
2022
Q1
$66.4M Buy
6,947,947
+648,124
+10% +$6.2M ﹤0.01% 2159
2021
Q4
$69.6M Buy
6,299,823
+443,268
+8% +$4.9M ﹤0.01% 2173
2021
Q3
$43.3M Buy
5,856,555
+577,586
+11% +$4.27M ﹤0.01% 2436
2021
Q2
$76.7M Buy
5,278,969
+763,854
+17% +$11.1M ﹤0.01% 2137
2021
Q1
$92.2M Sell
4,515,115
-139,194
-3% -$2.84M ﹤0.01% 1990
2020
Q4
$82.7M Buy
4,654,309
+79,431
+2% +$1.41M ﹤0.01% 1928
2020
Q3
$67.6M Sell
4,574,878
-123,496
-3% -$1.83M ﹤0.01% 1867
2020
Q2
$98.6M Buy
4,698,374
+265,318
+6% +$5.57M ﹤0.01% 1684
2020
Q1
$102M Buy
4,433,056
+429,454
+11% +$9.92M ﹤0.01% 1515
2019
Q4
$104M Sell
4,003,602
-5,431
-0.1% -$141K ﹤0.01% 1732
2019
Q3
$78.1M Buy
4,009,033
+76,246
+2% +$1.49M ﹤0.01% 1854
2019
Q2
$64.2M Buy
3,932,787
+54,562
+1% +$891K ﹤0.01% 1973
2019
Q1
$87.9M Sell
3,878,225
-101,835
-3% -$2.31M ﹤0.01% 1814
2018
Q4
$102M Buy
3,980,060
+308,030
+8% +$7.88M ﹤0.01% 1670
2018
Q3
$120M Buy
3,672,030
+126,135
+4% +$4.12M ﹤0.01% 1713
2018
Q2
$80.4M Buy
3,545,895
+108,949
+3% +$2.47M ﹤0.01% 1881
2018
Q1
$83.3M Buy
3,436,946
+38,614
+1% +$936K ﹤0.01% 1810
2017
Q4
$94.8M Buy
3,398,332
+105,277
+3% +$2.94M ﹤0.01% 1750
2017
Q3
$113M Buy
3,293,055
+95,778
+3% +$3.28M 0.01% 1636
2017
Q2
$127M Buy
3,197,277
+116,981
+4% +$4.66M 0.01% 1533
2017
Q1
$113M Buy
3,080,296
+125,223
+4% +$4.61M 0.01% 1589
2016
Q4
$94.2M Buy
2,955,073
+279,926
+10% +$8.92M 0.01% 1653
2016
Q3
$96.9M Buy
2,675,147
+223,581
+9% +$8.1M 0.01% 1578
2016
Q2
$55.6M Buy
2,451,566
+497,350
+25% +$11.3M ﹤0.01% 1854
2016
Q1
$36.7M Buy
1,954,216
+156,695
+9% +$2.95M ﹤0.01% 2006
2015
Q4
$29.5M Buy
1,797,521
+134,114
+8% +$2.2M ﹤0.01% 2136
2015
Q3
$18.3M Buy
1,663,407
+59,985
+4% +$659K ﹤0.01% 2323
2015
Q2
$20.9M Buy
1,603,422
+23,555
+1% +$307K ﹤0.01% 2336
2015
Q1
$27.4M Buy
1,579,867
+93,842
+6% +$1.63M ﹤0.01% 2195
2014
Q4
$22.2M Buy
1,486,025
+18,779
+1% +$280K ﹤0.01% 2197
2014
Q3
$33.8M Buy
1,467,246
+96,664
+7% +$2.23M ﹤0.01% 1986
2014
Q2
$43.7M Buy
+1,370,582
New +$43.7M ﹤0.01% 1897